Company Fined After Ayurvedic Pills Containing Deadly Lead Levels Poison Customer

A Singapore-based company, Herbal Pharm, has been fined S$3,000 after authorities discovered its ayurvedic products contained toxic levels of lead. The penalty follows a consumer report involving a patient who required hospitalization due to lead poisoning after consuming the pills.

The Health Sciences Authority (HSA) of Singapore identified the substance in a product marketed as “Himalaya Ashvagandha.” Laboratory testing conducted by the agency confirmed that the lead content in the supplement was significantly higher than the acceptable safety limits established for traditional medicines. According to the HSA, the contaminated pills posed a severe risk to consumer health, as heavy metal accumulation can lead to organ damage and neurological complications.

The investigation was triggered when a customer sought medical treatment for symptoms consistent with heavy metal toxicity. Subsequent clinical evaluation and follow-up testing confirmed the patient had been poisoned by the lead contained within the ayurvedic supplement. Upon notification, the HSA initiated a recall of the affected batches from the retail market to prevent further exposure.

Under the Health Products Act in Singapore, companies are legally required to ensure that all health supplements and traditional medicines are free from adulterants, including heavy metals like lead, mercury, and arsenic. The HSA maintains a rigorous testing regime for products sold in the country, noting that while traditional medicines are often perceived as natural, they are not exempt from the standards governing pharmaceutical safety.

Herbal Pharm has since removed the product from circulation. The company’s failure to ensure the safety of the items prior to sale resulted in the conviction under the Health Products (Health Supplements) Regulations.

The HSA has advised consumers who have purchased ayurvedic or traditional supplements to verify their safety status through official regulatory channels and to consult a medical professional if they experience unexplained health issues after consumption. The agency continues to monitor the market for non-compliant health products and has indicated that further enforcement actions remain a possibility should other products fail to meet safety mandates.